ProKidney FY2026 Earnings Forecast Lowered by HC Wainwright

ProKidney Corp. (NASDAQ:PROK – Free Report) – Equities researchers at HC Wainwright cut their FY2026 earnings estimates for ProKidney in a research note issued to investors on Friday, November 13th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.63) per share for the year, down from their previous estimate of ($0.52). The consensus estimate for ProKidney’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for ProKidney’s Q4 2026 earnings at ($0.16) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.58) EPS and FY2029 earnings at ($0.42) EPS.

ProKidney (NASDAQ:PROK – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.12 million.

PROK has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of ProKidney in a report on Tuesday, October 6th. Citigroup dropped their price objective on shares of ProKidney to $8.00 and set a “buy” rating for the company in a report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.00.

View Our Latest Stock Analysis on ProKidney

ProKidney Price Performance

PROK stock opened at $1.04 on Tuesday. ProKidney has a one year low of $0.87 and a one year high of $2.65. The firm has a 50 day simple moving average of $1.48 and a two-hundred day simple moving average of $1.75.

Hedge Funds Weigh In On ProKidney

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its stake in shares of ProKidney by 163.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 15,958 shares of the company’s stock valued at $26,000 after acquiring an additional 9,908 shares during the last quarter. SummitTX Capital L.P. bought a new position in ProKidney during the 1st quarter worth approximately $26,000. Cetera Investment Advisers bought a new position in ProKidney during the 3rd quarter worth approximately $27,000. StoneX Group Inc. bought a new position in ProKidney during the 3rd quarter worth approximately $30,000. Finally, Amundi increased its stake in ProKidney by 7.2% in the 1st quarter. Amundi now owns 291,708 shares of the company’s stock worth $522,000 after purchasing an additional 19,466 shares during the period. 51.59% of the stock is currently owned by institutional investors.

About ProKidney

(Get Free Report)

ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.

Read More

Earnings History and Estimates for ProKidney (NASDAQ:PROK)

Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.